The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome-Reference-Cited by-同舟云学术

The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome

Published:2022-12 Issue: Volume:68 Page:104143
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Longbrake Erin E.,Hua Le H.,Mowry Ellen M.,Gauthier Susan A.,Alvarez Enrique,Cross Anne H.,Pei Jinglan,Priest Jessica,Raposo Catarina,Hafler David A.,Winger Ryan C.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference56 articles.

1. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes;Amato;Neurology,2012

2. Radiologically isolated syndrome is antiquated amidst evolving McDonald criteria for multiple sclerosis;Avasarala;CNS Spectr.,2021

3. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: implications for SARS-CoV-2 vaccinations in multiple sclerosis;Baker;Mult. Scler. Relat. Disord.,2021

4. The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis;Baker;Mult. Scler. Relat. Disord.,2020

5. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis;Barkhof;Brain,1997

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiologically isolated syndromes: to treat or not to treat?;Journal of Neurology;2024-03-19

2. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines;Multiple Sclerosis and Related Disorders;2024-03

3. Emerging imaging markers in radiologically isolated syndrome: implications for earlier treatment initiation;Neurological Sciences;2024-02-19

4. Radiologically isolated syndrome;The Lancet Neurology;2023-11

5. Identification and management of subclinical disease activity in early multiple sclerosis: a review;Journal of Neurology;2023-10-21